NCT07383571

Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography

Safety and Efficacy of Oral Hyoscine Butylbromide Versus Topical EMLA Spray in Reducing Pain During Hysterosalpingography: A Randomized Double-Blind Placebo-Controlled Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 102 (estimated)
• Sponsor: Cairo University · Academic / Other
• Sex: Female
• Age: —
• Healthy volunteers: Not accepted

Summary

This randomized, double-blind, placebo-controlled, will evaluate whether oral hyoscine butylbromide or topical eutectic lidocaine-prilocaine (EMLA) spray reduces pain during hysterosalpingography (HSG) compared with placebo

Detailed description

This randomized, double-blind, placebo-controlled, three-arm clinical trial will evaluate whether oral hyoscine butylbromide or topical eutectic lidocaine-prilocaine (EMLA) spray reduces pain during hysterosalpingography (HSG) compared with placebo

Conditions

• Hysterosalpingography

Interventions

Type	Name	Description
DRUG	Oral Hyoscine butylbromide and Placebo Spray	Hyoscine butylbromide 20 mg oral tablet, single dose 30 min before HSG PLUS placebo cervical spray
DRUG	Topical EMLA Spray and Placebo Oral Tablet	EMLA spray (lidocaine 2.5% + prilocaine 2.5%), 3 sprays to ectocervix/external os, 10 min before HSG plus placebo oral tablet
OTHER	Double Placebo	oral placebo tablet plus placebo cervical spray

Timeline

• Start date: 2025-10-03
• Primary completion: 2026-03-01
• Completion: 2026-03-30
• First posted: 2026-02-03
• Last updated: 2026-02-03

Locations

1 site across 1 country: Egypt